Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:24 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dopamine D3 Receptor Occupancy in Bipolar Depression
NCT05060549 · New York State Psychiatric Institute · PHASE4 · withdrawn · last registry update 2026-04-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding decision” | – | Registry record, New York State Psychiatric Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (terminated): Negovsky Reanimatology Research Institute, Sevoflurane + Propofol (NCT05259631)
- 2026-11-02Results posted on the registry: Response Pharmaceuticals, RDX-002 + Olanzipine + Olanzapine (NCT05857566)
- 2026-10-08Results posted on the registry: Corey Hawes, Cyproheptadine + Olanzapine (NCT06175273)
- 2026-09-14Also stopped (terminated): Denovo Biopharma LLC, LY2140023 + Olanzapine (NCT01129674)
- 2026-09-02Results posted on the registry: The Guthrie Clinic, OLA group: Olanzapine + DEX group: Dexamethasone (NCT05590923)
- 2026-09-02Also stopped (terminated): The Guthrie Clinic, OLA group: Olanzapine + DEX group: Dexamethasone (NCT05590923)
- 2026-07-28Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Clonazepam + Olanzapine (NCT06133114)
- 2026-07-23Phase 3 first posted: Bostal Drug Delivery Co., Ltd, 30 mg B2227 + 70 mg B2227 (NCT07722728)
- 2026-07-21Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Auricular point stimulation plus dexamethasone + Standard pharmacologic antiemetic regimen (NCT07716189)
- 2026-07-21Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Auricular point stimulation plus dexamethasone + Standard pharmacologic antiemetic regimen (NCT07716228)
- 2026-07-21Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Auricular point stimulation plus dexamethasone + Standard pharmacologic antiemetic regimen (NCT07716176)
- 2026-07-16Results posted on the registry: Yale University, Olanzapine + Placebo (NCT05676294)
- 2026-07-14Also stopped (suspended): National Institute of Allergy and Infectious Diseases (NIAID), Pramipexole ER + Escitalopram (NCT06705478)
- 2026-06-30Results posted on the registry: Teva Branded Pharmaceutical Products R&D LLC, TV-44749 318mg + Oral Olanzapine 10mg/day (NCT06253546)
- 2026-06-24Phase 3 first posted: Daniel Lindqvist, Pramipexole + Placebo (NCT07664852)
- 2026-06-08Phase 3 first posted: Blokhin's Russian Cancer Research Center, OLANZapine 2.5 MG (NCT07633236)
- 2026-05-26Phase 3 first posted: University Medical Center Groningen, a drug against DRD3 (NCT07606014)
- 2026-05-13Results posted on the registry: University Hospital, Clermont-Ferrand, Dexmedetomidine (NCT03317067)
- 2026-05-04Phase 3 first posted: Minerva Neurosciences, Roluperidone + risperidone (NCT07565428)
- 2026-03-09Also stopped (withdrawn): Universidad Europea de Canarias, pharmacological treatment by Opioids (NCT06240390)
- 2026-02-25Also stopped (terminated): Ohio State University, Clozapine + Antipsychotics,Other (non-Clozapine) (NCT05741502)
- 2026-02-17Phase 3 first posted: The Affiliated People's Hospital of Ningbo University, Fosaprepitant + Fosaprepitant (NCT07413809)
- 2026-01-26Results posted on the registry: Teva Branded Pharmaceutical Products R&D LLC, Olanzapine Extended Release + Olanzapine Immediate Release (NCT06319170)
- 2026-01-09Results posted on the registry: Teva Branded Pharmaceutical Products R&D LLC, TV-44749 + Placebo (NCT05693935)
- 2025-12-15Also stopped (terminated): Areteia Therapeutics, Dexpramipexole Dihydrochloride (NCT06388889)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision